Research programme: cardiovascular disorder therapeutics - 4SC Discovery/University of Munich
Latest Information Update: 25 Apr 2014
At a glance
- Originator 4SC Discovery
- Developer 4SC Discovery; University of Munich
- Class Small molecules
- Mechanism of Action ADAM protein modulators; Histone deacetylase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders
Most Recent Events
- 15 Apr 2014 Early research in Cardiovascular disorders in Germany (unspecified route)